Monoclonal antibodies and the treatment of systemic lupus erythematosus
Article Sidebar
Main Article Content
Abstract
Systemic lupus erythematosus is a chronic autoimmune disease that involves the production of certain antibodies throughout the body and the consequent inflammation of connective tissue, as well as skin, hematological, and cardiovascular conditions, among others. Postulates about its origin vary from a genetic to an environmental, an immunological or a hormonal one, but actually its etiology is unknown. Conventional treatment is based on the severity of its clinical manifestations. The first line of treatment is the administration of antimalarial drugs, immunosuppressants, glucocorticoids, and methotrexate. For many years, all of these medications have given some relief to patients suffering from this disease. Unfortunately, they are not very selective, reason why they cause serious adverse effects to the patients. Given this situation, the use of biological therapies has been sought; these have the advantage of being more specific. One of them are the monoclonal antibodies, such as belimumab, which have reduced the risk of flares and have improved the serological activity of patients. Therefore, research focused on biological therapy for the treatment of different autoimmune diseases such as systemic lupus erythematosus is being expanded every day.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores conservan los derechos de autor y ceden a la revista el derecho de la primera publicación y pueda editarlo, reproducirlo, distribuirlo, exhibirlo y comunicarlo en el país y en el extranjero mediante medios impresos y electrónicos. Asimismo, asumen el compromiso sobre cualquier litigio o reclamación relacionada con derechos de propiedad intelectual, exonerando de responsabilidad a la Editorial Tecnológica de Costa Rica. Además, se establece que los autores pueden realizar otros acuerdos contractuales independientes y adicionales para la distribución no exclusiva de la versión del artículo publicado en esta revista (p. ej., incluirlo en un repositorio institucional o publicarlo en un libro) siempre que indiquen claramente que el trabajo se publicó por primera vez en esta revista.
References
M. S. Mohd Shahrir, A. G. Abdul Halim, Z. Soehardy, and C. T. Norella Kong, “Clinical experience in using CD20 monoclonal antibody in treating severe systemic lupus erythematosus,” APLAR Journal of Rheumatology, 10, 112-116, 2007.
R. I. L. Machado, M. A. Scheinberg, M. Y. C. F. Queiroz, D. C. S. E. Brito, M. F. B. R. Guimarães, R. A. Giovelli et al., “Use of rituximab as a treatment for systemic lupus erythematosus: Retrospective review,” Einstein, 12(1), 36-41, 2014.
H. M. A. Ahmed, S. Abohamad, M. Elfishawi, M. T. Hegazy, and K. Vijaykumar, “Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: A critical review with focus on safety and satisfaction,” Patient Preference and Adherence, 12, 2475-2479, 2018.
J. A. Gómez-Puerta y R. Cervera, “Lupus eritematoso sistémico”, Medicina & Laboratorio, 14(5-6), 211-223, 2008.
M. L Specchia, C. de Waure, M. R. Gualano, A. Doria, G. Turchetti, L. Pippo et al., “Health technology assessment of belimumab: A new monoclonal antibody for the treatment of systemic lupus erythematosus,” BioMed Research International, 2014, 704207, 2014.
R Sakthiswary and E. Suresh, “Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy,” Lupus, 23(3), 225-235, 2014.
M. A. Villalobos Zúñiga, “Enfermedades infecciosas en pacientes con lupus eritematoso sistémico en el Hospital Calderón Guardia: caracterización, incidencia, profilaxis y factores asociados”, Revista Clínica de la Escuela de Medicina UCR – HSJD, 2(6), 21-34, 2012.
F. Schaper, M. M. van Timmeren, A. Petersen, G. Horst, M. Bijl, P. C. Limburg et al., “Treatment with anti-HMGB1 monoclonal antibody does not affect lupus nephritis in MRL/Ipr mice,” Molecular Medicine, 22, 12-21, 2016.
J. S. Hui-Yuen, S. C. Nguyen, and A D. Askanase, “Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus,” Lupus, 25(10), 1086-1096, 2016.
J. F. Flores-Ramírez, H. García-Bernal, E. U. Morales-León y C. U. Islas-Martínez, “Usos de anticuerpos monoclonales en medicina”, TEXEPI, Boletín Científico de la Escuela Superior Tepeji del Río, 11, 25-28, 2019.
L. Zurita-Gavilanes and A. Costa-Valarezo, “Rituximab in lupus nephritis: A non-systematic review,” Reumatología Clínica, 12(4), 210-215, 2016.
M. Enberg, M. Kahn, C. Goity, M. V. Villalón, J. Zamorano, F. Figueroa, “Infecciones en pacientes con lupus eritematoso sistémico”, Revista Médica de Chile, 137(10), 1367-1374, 2009.
P. Toche, “Visión panorámica del sistema inmune”, Revista Médica Clínica Las Condes, 23(4), 446-457, 2012.
X. Filella, R. Molina, A. M. Ballesta, “Estructura y función de las citocinas”, Medicina Integral, 39(2), 63-71, 2002.
D. M. Barahona-López, L. E. Sánchez-Sierra, C. F. Matute-Martínez, I. A. Barahona-López, R. Perdomo-Vaquero, G. Erazo-Trimarchi, “Hospitalización en lupus eritematoso sistémico: causas, actividad lúpica y evolución”, Medicina Interna de México, 33(6), 730-738, 2017.
L. Esquivel-Pedraza, L. Fernández-Cuevas, Y. M. Sánchez-Jiménez, J. Domínguez-Cherit y S. Méndez-Flores, “Lesiones de la mucosa bucal por administración de metotrexato en pacientes con artritis reumatoide”, Dermatología, Revista Méxicana, 61(6), 492-499, 2017.
M. E. Alfonso-Valdés, “Inmunopatogenia de la psoriasis: impacto en las manifestaciones clínicas y el tratamiento de la enfermedad”, Revista Cubana Hematología, Inmunología y Hemoterapia, 28(4), 357-373, 2012.
A. A. Hernández-Collazo, A. C. Rodríguez-Mena, M. R. Ferrusco-Ontiveros, E. D. Poletti-Vázquez, “Estomatitis por metotrexato y sus efectos orales a bajas dosis”, Dermatología, Revista Mexicana, 58, 458-464, 2014.
T. Li, S. L. Chen, D. E. Furst, C. D. Bao, L. Li, and S. Chen, “A 1-year study of two doses of steroid in combination with methotrexate and chloroquine in the treatment of patients with mild and moderate systemic lupus erythematosus,” APLAR Journal of Rheumatology, 9, 392-396, 2006.
M. N. Islam, M. Hossain, S. A. Haq, M. N. Alam, P. M. Ten Klooster, and J. J. Rasker, “Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus,” International Journal of Rheumatic Diseases, 15(1), 62-68, 2012.
B. Brochet, M. S. A. Deloire, P. Perez, T. Loock, L. Baschet, M. Debouverie et al., “Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis,” PLoS ONE, 12(1), e0168834, 2017.
D. R. G. El-Karim and G. El-Amrawi, “Cyclophosphamide hepatotoxicity: The role of 4-hydroxynonenal and cytochrome C oxidase and the possible protective effect of Ganoderma lucidum extract,” Slovenian Veterinary Research, 56(Suppl 22), 15-23, 2019.
D. Chen, F. Lian, S. Yuan, Y. Wang, Z. Zhan, Y. Ye et al., “Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus,” Clinical Rheumatology, 33(4), 499-503, 2014.
N. H. Borazan y D. E. Furst, “Fármacos antiinflamatorios no esteroideos, antirreumáticos modificadores de la enfermedad, analgésicos no opioides y fármacos usados en la gota”, en Farmacología básica y clínica (13.a ed.), B. G. Katzung y A. J. Trevor, Eds. México DF: Mc Graw-Hill Interamericana Editores, 2016.
S. Zhang, X. Liu, L. Cai, J. Zhang, and C. Zhou, “Longitudinal melanonychia and subungual hemorrhage in a patient with systemic lupus erythematosus treated with hydroxychloroquine,” Lupus, 28(1), 129-132, 2019.
A. Danza, D. Graña, M. Goñi, A. Vargas y G. Ruiz-Irastorza, “Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes sistémicas,” Revista Médica de Chile, 144(2), 232-240, 2016.
M. Gatto, M. Zen, L. Iaccarino, and A. Doria, “New therapeutic strategies in systemic lupus erythematosus management,” Nature Reviews Rheumatology, 15(1), 30-48, 2019.
A. Fanouriakis, C. Pamfil, P. Sidiropoulos, L. Damian, A. Flestea, G. Gusetu et al., “Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: A retrospective, observational two-centre study,” Lupus, 25(6), 627-636, 2016.
T. Igarashi, T. Igarashi, A. Shimizu, and Y. Itoh, “Intravenous Cyclophosphamide Pulse Therapy in Japanese Children with Systemic Lupus Erythematosus,” Journal of Nippon Medical School, 80(5), 396-400, 2013.
A. Chico Capote, M. Estévez del Toro, J. F. Gálvez Vallejo, D. Chía Proenza y A. Chong López, “Glomerulopatía colapsante en lupus eritematoso sistémico con respuesta positiva a tratamiento con mofetil micofenolato,” Revista Cubana de Medicina, 57(2), 1-6, 2018.
A. M. Krensky, J. R. Azzi, and D. A. Hafler, “Immunosuppressants and Tolerogens,” en Goodman & Gilman’s. The Pharmacological Basis of Therapeutics, 13th ed., L. L. Brunton, R. Hilal-Dandan, and B. C. Knollmann, Ed. Estados Unidos: McGraw-Hill Education, 2018.
O. L. Vera-Lastra, A. Olvera-Acevedo, C. Hernández, G. Medina, A. N. Carillo-González, U. Ángeles-Garay et al., “Efecto de pravastatina más ezetimibe en el grosor intimamedia carotídea en pacientes con lupus eritematoso,” Revista Médica del Instituto Mexicano del Seguro Social, 53(Supl. 1), S74-S79, 2015.
S. Kabadi, J. Yeaw, A. K. Bacani, E. Tafesse, K. Bos, S. Karkare et al., “Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus,” Lupus, 27(11), 1799-1809, 2018.
J. L. Englund and W. P. Kerns II, “Beta Bloqueadores,” Medicina de Urgencias, 8.a ed., J. E. Tintinalli, J. S. Stapczynski, O. J. Ma, D. M. Yealy, G. D. Meckler, and D. M Cline, Ed. Estados Unidos: McGraw-Hill Education, 2018.
P. Bienias, M. Ciurzyński, A. Chrzanowska, I. Dudzik-Niewiadomska, K. Irzyk, K. Oleszek et al., “Attenuated post-exercise heart rate recovery in patients with systemic lupus erythematosus: the role of disease severity and beta-blocker treatment,” Lupus, 27(2), 217-224, 2018.
“Antibodies,” Review of Medical Microbiology and Immunology, 14th ed., W. Levinson, Ed. Estados Unidos: McGraw- Hill, 2016.
D. Sadava, G. Heller, G. Orians, W. Purves, and D. Hillis, Vida: la ciencia de la biología, 8.a ed. Buenos Aires: Editorial Médica Panamericana, 2009.
“Base celular de la respuesta inmunitaria,” Biología celular y molecular, 4.a ed., R. Paniagua, M. Nistal, P. Sesma, M. Álvarez-Uría, B. Fraile, R. Anadón et al., Eds. Madrid: McGraw-Hill/Interamericana de España, 2017.
S. Magadán y A. González-Fernández, “Generación de anticuerpos monoclonales in vivo,” Anticuerpos monoclonales: realidades y perspectivas, L. Álvarez Vallina, Ed. Madrid: Editorial Complutense, S.A, 2004.
N. P. Machado, G. A. Téllez y J. C. Castaño, “Anticuerpos monoclonales: desarrollo físico y perspectivas terapéuticas,” Infectio, 10(3), 186-197, 2006.
E. R. García Calvo, “Anticuerpos monoclonales en el tratamiento de cáncer,” tesis, Universidad Complutense, Madrid, España, 2016.
B. Laffleur, V. Pascal, C. Sirac, and M. Cogné M, “Production of human or humanized antibodies in mice,” Antibody Methods and Protocols. Methods in Molecular Biology (Methods and Protocols), G. Proetzel and H. Ebersbach, Eds. Nueva Jersey: Humana Press, 2012.
P. Mayrhofer and R. Kunert, “Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives,” Human Antibodies, 27, 37-51, 2019.
S. A. Yeoh, S. S. Dias, and D. A. Ienberg, “Advances in systemic lupus erythematosus,” Medicine, 46(2), 84-92, 2018.
Food and Drug Administration (2019, April 26). FDA approves first treatment for pediatric patients with lupus. [En línea]. Disponible en: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-pediatric-patients-lupus
U. Hafeez, H. K. Gan, and A. M. Scott, “Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases,” Current Opinion in Pharmacology, 41: 114-121, 2018.
F. Marcondes and M. Scheinberg, “Belimumab in the treatment of systemic lupus erythematous: An evidence based review of its place in therapy,” Autoimmunity Reviews, 17(2), 103-107, 2018.
S. V. Navarra, R. M. Guzmán, A. E. Gallacher, S. Hall, R. A. Levy, R. E. Jimenez et al., “Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomized, placebo-controlled, phase 3 trial,” The Lancet, 377(9767), 721-731, 2011.
R. Furie, M. Petri, O. Zamani, R. Cervera, D. J. Wallace, D. Tegzová et al., “A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus,” Arthritis & Rheumatism, 63(12), 3918-3930, 2011.
D. Ramsköld, I. Parodis, T. Lakshmikanth T, N. Sippl, M. Khademi, Y. Chen et al., “B cell alterations during BAFF inhibition with belimumab in SLE,” EbioMedicine, 40, 517-527, 2019.
National Institute for Health and Care Excellence, “Belimumab for treating active autoantibody-positive systemic lupus erythematosus,” National Institute for Health and Care Excellence, Londres, Technology Appraisal Guidance, TA397, 2016.
Ministerio de Salud (2019, mayo 30). Consulta de productos registrados en plataforma. [En línea]. http://registrelo.go.cr/cfmx/ms/consultasPublicas/
J. Sopp and M. S Cragg. “Deleting malignant B cells with second-generation anti-CD20 antibodies,” Journal of Clinical Oncology, 36(22), 2323-2325, 2018.
L. Lei, S. Muhammad, M. Al-Obaidi, N. Sebire, I. L. Cheng, D. Eleftheriou et al., “Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ,” Pediatric Rheumatology, 16(1), 61, 2018.
J. Bakshi, M. Ismajli, and A. Rahman, “New therapeutic avenues in SLE,” Best Practice & Research Clinical Rheumatology, 26(6), 794-809, 2015.
F. Speth, C. Hinze, and R. Häfner, “Combination of ofatumumab and fresh frozen plasma in hypocomplementemic systemic lupus erythematosus: A case report,” Lupus, 27(8), 1395-1396, 2018.
A. R. Moschen, H. Tilg, and T. Raine, “IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting,” Nature Reviews Gastroenterology & Hepatology, 16(3), 185-196, 2019.
A. Fava and M. Petri, “Systemic lupus erythematosus: Diagnosis and clinical management,” Journal of Autoimmunity, 96, 1-13, 2019.
G. M. Doody, L. B. Justement, C. C. Delibrias, R. J. Matthews, J. Lin, M. L. Thomas et al., “A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP,” Science, 269(5221), 242-244, 1995.
A. Mohamed, Y. Chen, H. Wu, J. Liao, B. Cheng, and Q. Lu, “Therapeutic advances in the treatment of SLE,” International Immunopharmacology, 72, 218-223, 2019.
M. E. Drago Serrano y T. R. Sainz Espuñes, “Sistemas de expresión para proteínas terapéuticas recombinantes,” Revista Mexicana de Ciencias Farmacéuticas, 37(1), 38-44, 2006.
R. W. Carrell, J. O. Jeppsson, C. B. Laurell, S. O. Brennan, M. C. Owen, L. Vaughan et al., “Structure and variation of human α1–antitrypsin,” Nature, 298(5872), 329-334, 1982.
A. S. Elshikha, Y. Yuan, Y. Lu, M. J. Chen, G. Abboud, M. A. Akbar et al., “Alpha 1 antitrypsin gene therapy extends the lifespan of lupus-prone mice,” Molecular Therapy Methods & Clinical Development, 11, 131-142, 2018.
J. Barbado, S. Tabera, A. Sánchez, and J. García-Sancho, “Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis,” Lupus, 27(13), 2161-2165, 2018.